Charles Baltic

Mr. Baltic has served as a Director of MEI Pharma, a publicly-traded development-stage biotechnology company focused on hematology/oncology (MEIP – Nasdaq CM), since October 2011 and as Chair of its Nominating and Governance Committee since 2012. Mr. Baltic has been affiliated with Needham & Company, LLC since 2009, as Managing Director and Co-Head of Healthcare Banking until 2019 and as Senior Advisor from 2019. Mr. Baltic has served as acting CEO of Amyndas Pharmaceuticals, a private development-stage biotechnology company focused on immunology and innate immunity complement therapeutics based on technology licensed from the University of Pennsylvania, since March 2021. Mr. Baltic served as Executive Vice President and COO of SIDIS Corp., a private life sciences management and investment company, from 2019, where he oversaw the execution of the sale of the Propel Labs flow cytometry business to Thermo Fisher Scientific in February 2021. Mr. Baltic was a Managing Director and Head of the biotechnology practice at CRT Capital Group from 2006 to 2008. From 2001 to 2006, he served as a Managing Director in Healthcare Investment Banking at Wachovia Securities. Prior to Wachovia, he was with Healthcare Investment Banking at Cowen and Company for six years, ultimately serving as a Director. Prior to beginning his investment banking career in 1996, Mr. Baltic practiced corporate and securities law with the firm of Dewey Ballantine, representing numerous healthcare and securities clients. Mr. Baltic previously served as a Director of SIDIS from 2015 - 2019. Mr. Baltic served as a Director of the non-profit trade association Life Science Washington from 2013 to 2018. He served as a Director of MedVantage Inc., a private health informatics company that was ultimately acquired by IMS Health (now IQVIA Holdings), in 2011. Mr. Baltic served as a member of the U.S. Securities and Exchange Commission’s Advisory Committee on Small and Emerging Growth Companies from 2013 to 2015. He served as a founding Trustee of the non-profit Hope Funds for Cancer Research from 2007 to 2017. Mr. Baltic earned a B. A (honors) and J.D. degrees from Georgetown University and an M.B.A. degree in finance from the Wharton School of the University of Pennsylvania.